Articles related to MYELOMA

The authors evaluated the treatment approaches and outcomes of 110 patients with primary plasma cell leukemia (pPCL) in this retrospective study . Higher complete response rates were associated with treatment with bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab-based quadruplets (DBQ) and autologous stem-cell transplantation. Patients who received VRd/DBQ had better outcomes than those who received other bortezomib-based combinations or standard chemotherapy.

The article reports that a new blood test, called the EasyM protocol, has been certified by the US Food and Drug Administration (FDA) for use in detecting multiple myeloma relapse. The test works by detecting small amounts of circulating tumor DNA (ctDNA) in the blood, which can indicate the presence of residual disease. The EasyM protocol is reportedly more sensitive than existing tests for detecting ctDNA, and can provide results in just a few hours. The article notes that the test has the potential to improve patient outcomes by allowing for earlier detection of relapse and more personalized treatment options.

Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, cell therapy experts, and other HCPs actively involved in the care of patients with multiple myeloma should be better able to:

By using mass cytometry (CyTOF) analysis, the researchers profiled plasma cells (PCs) and their B cell lymphopoiesis in BM samples from patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma (MM), and active MM in order to better understand the heterogeneity of MM.

In conclusion, daratumumab (Darzalex) (D) was added to lenalidomide, bortezomib, and dexamethasone (RVd) in NDMM patients who were transplant-eligible, and this led to enhanced stringent complete response (sCR) and minimal residual disease (MRD)-negative rates, a tolerable safety profile, and no clinically meaningful effects on stem cell mobilization or engraftment. These findings suggest that the D-RVd combination may become a new standard of care for NDMM who are transplant-eligible.

To gain access to its primary experimental medication for a rare blood cancer and complement Blenrep, currently indicated as a treatment for patients with relapsed or refractory multiple myeloma who received at least four prior therapies, the company decided to purchase American pharmaceutical company Sierra Oncology in April. However, in patients with relapsed or refractory multiple myeloma, Blenrep did not achieve the primary endpoint of progression-free survival, according to a statement from GSK, which saw its shares fall 3% upon the announcement.